biotechnolog field report kol panel takeaway market dynam multipl myeloma lymphoma
technolog media telecommun secur infrastructur softwar take aw invent
medic suppli devic chart week down sc med-tech valuat track end
 power forward power curv genco mtm weekli commentari
page analyst certif import disclosur
media internet commun daili daili global app data show snap ig tiktok strength novemb
 highlight investor meet buy
publish decemb
messag pleas host cfo barri zwarenstein presid burkland investor meet ny boston
management emphas custom experi becom essenti brand digit transform project expand role data-
driven ai/ml go beyond autom improv qualiti interact believ well posit take advantag industri shift
slew new featur come potenti expand beyond much larger labor contact center
reiter buy rate share rais pt
 buy oper model potenti continu shineawait
global brand valid rais estim pt
publish decemb
messag late septemb set two import market share driversr estat transform product innovation/brand
extensionsback motion concurr first time four year see preview look envis
return double-digit revenu growth appear post may launch earlier-than-anticip vs
meaning potenti catalyst investor sentiment global brand valid revenu given potenti growth contribut rais
estim price target accordingli reiter out-of-consensu buy
page analyst certif import disclosur
san-par focu pipelin leverag spin
consum bd
publish decemb
messag sanofi host capit market day cambridg anticip follow focu meet
ceo paul hudson deliv strateg vision busi includ pipelin beyond collabor blockbust dupix
leverag opportun busi develop includ divestitur depriorit busi potenti a/partnership deliv
compani robust emerg market presenc remain buy rate san-par pt
publish decemb
messag updat estim reflect recent report result manag commentari
maintain buy rate price target reiter neutral rate
publish decemb
messag given magnitud guide-down view modest beat clear posit especi sinc deliv gross
margin expans basi point face elev industry-wid promot activ bottom line although recent downtrend make-up
categori hinder compani abil deliv long-term secular growth algorithmcomp ep mid-to-high single-digit
remain well-posit secular share gain consensu expect appear reason rel valuat look
attract us exhibit reiter buy rate price target exhibit
page analyst certif import disclosur
publish decemb
messag key takeaway kol event host argx includ scientif rational use anti-fcrn cidp promis
though sever unknown remain propos phase ii cidp trial efgartigimod clever design believ could larg enrich trial
high respond bias readout argx favor though estim interim data may come earli phase data share
first time enhanze-modifi subq efgartigimod look promis demonstr non-inferior iv efgartigimod igg deplet
possibl allow qw dose
still durabl though variabl increas
publish decemb
messag saturday sgmo/pf present updat data poster data vs wk
abstract first pt treat highest dose show continu durabl factor express normal next patient
treat dose also reach normal rang averag far lower factor express bit variabl particularli patient
bottom line continu think data meaning number pt necessari get better sens competit profil
therapi takeaway poster session data detail
field report kol panel takeaway market dynam multipl myeloma lymphoma leukemia
publish decemb
messag host discuss panel three physician consult institut investor client follow present sunday
note summar key takeaway discuss physician special treatment multipl myeloma lymphoma
leukemia discuss focus highlight emerg therapi potenti impact current clinic practic within oncolog
page analyst certif import disclosur
buy avapritinib ism data compel safeti debat
goe new icb report asm studi
publish decemb
messag present initi data on-going ph ii pioneer studi kit inhibitor avapritinb indol system mastocytosi ism
updat result ph explor advanc sm host investor event one hand initi ism data look compel view
show potenti activ low avapritinib dose safeti profil indistinguish placebo hand report
grade icb one asm patient explor studi although confound sever thrombocytopenia head trauma think
continu debat investor avapritinib remain track potenti snda file maintain buy
sever mid-term potenti blockbust
publish decemb
messag novn manag share rang potenti blockbust opportun pipelin includ asset still early-
stage trial highlight potenti medium-term growth opportun could sustain compani top line growth profil among mani
opportun drive sustain growth manag expand number file china aim doubl sale year impress
us depth breadth innov novn portfolio phase asset pois deliv pivot data follow manag
feedback key question prior note link buy rate novn pt chf
buy investor event confirm pipelin track anti-
tumor activ observ patient
publish decemb
messag expect share recov follow compani investor event head first clinic data dose
escal studi non-engin ipsc-deriv nk cell therapi demonstr clean safeti profil yet limit clinic activ
phase studi consist investor expect preliminari clinic activ observ howev first two patient treat
high-affin nk posit surpris add pipelin asset track key mileston includ patient treat car-nk
ind submiss first ipsc-deriv car-t
page analyst certif import disclosur
cultur strengthen customer-domin model
publish decemb
messag name lawton presid ceo effect januari ceo greg sandfort previous announc
intent retir bottom line believ mr lawton optim choic given divers experi softlinestwo year presid
e-commercetwo year svp north america year depot merchandis organ well
understand appreci uniqu customer-domin brand current ceo greg sandfort remain compani advisori
role august believ transit seamless remain buy rate
publish decemb
messag host cfo ir ndr boston new york discuss focus partnership though manag
think benefit still month buy-back underway expect share grind higher publish report use shop
sale activ across black friday cyber monday forecast gmv suggest upsid vs consensu estim
attend aw invent spoke custom partner cloud adopt trend multi-cloud use grow custom shift
workload mani custom note prefer azur
zm post result revenu guidanc street custom nearli doubl report
strong quarter beat consensu estim across metric though book growth new custom add slow report revenu
ep street reiter guidanc guidanc consensu estim zs report revenu bill
street estim bill slightli investor recommend beat rais overshadow initi
revenu growth commentari street
decemb veeva ndr lo angel
publish decemb
messag gene therapi research move lightn speed progress alreadi made next-gen aav front much like new cell
phone everi year field collect continu work bring improv viral vector tabl aav though there lot
page analyst certif import disclosur
interest new virus engin viral mashup week highlight recent studi made librari new chimera
effort develop superior viral vector larg cargo high specif tropism low toxic know drill
secur infrastructur softwar take aw invent
publish decemb
messag attend aw invent confer vega week note present key take convers
custom partner
chart week down sc med-tech valuat track end right start
publish decemb
messag head home stretch small-cap med-tech index year solidli outpac russel
valuat standpoint small-cap med-tech group came year trade averag ntm high
octob still well long-term averag volatil year saw multipl go high low group
look pois finish start averag small-cap med-tech compani trade ntm sale today
teva neutral preview teva path expand gross margin
publish decemb
messag gross margin expans remain key teva long-term fundament stori achiev oper margin within year
accord compani note review histori gross margin expans novo lundbeck kare schultz ceo
respect compar teva push pull teva gross margin profil compani impli guidanc
neutral meet primari endpoint karmma set
bar competit lentiglobin updat
publish decemb
messag bmy/blu announc friday pivot karmma studi met primari endpoint result larg consist
observ ph posit news clinic activ set high efficaci bar potenti competitor anti-bcma product view
confirm remain track file karmma dataset earlier line remain on-going pipelin updat
page analyst certif import disclosur
lentiglobin larg consist expect view updat still pend news provid posit
momentum stock weak head data remain neutral rate
forward power curv genco mtm weekli commentari
publish decemb
weekli market polici highlight takeaway page report
messag week nation atc spark spread mix western market pacnw socal norcal desert sw
trade lower eastern market show modest improv except ison miso region illinoi
ercot pjm nyiso show improv atc power price lower across iso
averag power market show declin ercot lag least natur ga price took major
drop week report period henri hub price decreas ny pjm illinoi lead declin eastern market
respect texa ga saw declin entir off-set lower power price aggreg region dynam net
neg impact ipp genco mark week period ipp genco mark still higher vs end june mark
publish decemb
guggenheim host client util event includ ndr
schedul scroll
es connecticut select vineyard wind project off-shore wind rfp eversourc constitut wind
nc gov roy file run re-elect
d/duk/so call reject acp compressor station histor district union hill commun
vistra close acquisit ambit
ceo guldner appear decemb
solar intern trade commiss hold midterm hear solar tariff
opuc deni rehear vectren ohio rate case decis
page analyst certif import disclosur
daili global app data show snap ig tiktok strength novemb news spend
publish decemb
today top mind
app anni global novemb rank show strength tiktok whatsapp messeng instagram snapchat flat trend fb
wong raise pt roll valuat forward follow compani result includ tier cloud announc
consensu guid
zm amladi reiter buy rate zm revenu grew benefit scale growth plan seemingli track
koujalgi lower price target book momentum slow new custom add slightli y/i
page analyst certif import disclosur
inc
page analyst certif import disclosur
primari analyst jake fuller
page analyst certif import disclosur
primari analyst glen santangelo
page analyst certif import disclosur
explor product
page analyst certif import disclosur
primari analyst michael schmidt
primari analyst etzer darout
life scienc tool omic
primari analyst david westenberg cfa
page analyst certif import disclosur
